This brand name is authorized in Ecuador
The drug LOBRAXOL contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Ambroxol
UNII 200168S0CL - AMBROXOL
|
|
Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs. |
|
2
Loratadine
UNII 7AJO3BO7QN - LORATADINE
|
|
Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R05FB01 | Cough suppressants and mucolytics | R Respiratory system → R05 Cough and cold preparations → R05F Cough suppressants and expectorants, combinations → R05FB Other cough suppressants and expectorants |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 599-MEN-1115, 633-MEN-0116 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
